OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Interactive ToolsLearning ModulesPresentationsSponsored
Biomarker Consortium
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • 2024 nominations are open for Giants of Cancer Care®
  • In-person and virtual events just for HCPs
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
    • Biomarker Consortium
Advertisement

The Evolving Landscape of Molecular Alterations in NSCLC: Optimizing Testing and Treatment to Improve Outcomes : Episode 6

Molecular Testing in Advanced NSCLC: Recommended Targets and Methods

May 11, 2022
Ticiana A. Leal, MD
Video

Expert Ticiana Leal, MD, shares her perspective on routine molecular testing practices in advanced non–small cell lung cancer.

EP: 1.Overview of Actionable Mutations and Molecular Profiling in NSCLC

EP: 2.Optimizing the Use of Molecular Profiling in Non–Small Cell Lung Cancer

EP: 3.Is There a Role for IO Therapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements?

EP: 4.Poor Outcomes With IO Therapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

EP: 5.IO Therapy in NSCLC With Concomitant KRAS/TP53 Mutations

Now Viewing

EP: 6.Molecular Testing in Advanced NSCLC: Recommended Targets and Methods

EP: 7.Optimizing Use of Molecular Testing in Advanced NSCLC

EP: 8.Overcoming Barriers to Molecular Testing in NSCLC

EP: 9.Immunotherapy in NSCLC With Classical EGFR Mutations or ALK Rearrangements

EP: 10.Immunotherapy in NSCLC With Concomitant KRAS/STK11 or KRAS/KEAP1 Mutations

EP: 11.Immunotherapy in NSCLC With Concomitant KRAS/TP53 Mutations

EP: 12.Testing Strategies for Actionable Mutations in Non–Small Cell Lung Cancer

EP: 13.NSCLC: The Role of Liquid Biopsy in Molecular Testing and Treatment Decision-Making

EP: 14.Overcoming Barriers to Molecular Profiling in NSCLC Management

EP: 15.Is There a Role for PD-L1 Inhibitors in EGFR-Mutant or ALK-Rearranged NSCLC?

EP: 16.I/O Therapy in KRAS-Mutant NSCLC With Concomitant STK11 or KEAP1 Mutations

EP: 17.NSCLC: Immunotherapy in Patients With Concomitant KRAS/TP53 Mutations

Transcript:

Ticiana A. Leal, MD:Hello and welcome to this OncLive® program,“The Evolving Landscape of Molecular Alterations in Non–Small Cell Lung Cancer: Optimizing Testing and Treatment to Improve Outcomes.” I’m Dr Ticiana Leal, associate professor and director of the thoracic medical oncology program at the Winship Cancer Institute of Emory University [Madison, Wisconsin]. Today, I’m going to discuss a number of updates in the testing and treatment of molecular alterations in advanced non–small cell lung cancer. We’ll discuss the data in the context of the landscape and their impact on clinical practice. Let’s get started on our first topic.

For patients with advanced non–small cell lung cancer, we have moved forward with testing for actionable mutations at initial diagnosis. In 2003, EGFR was identified as a molecular biomarker in non–small cell lung cancer, followed by ALK in 2011. In the last decade, we’ve seen several more molecular and immune biomarkers emerge to help clinicians personalize a treatment plan for their patients with advanced non–small cell lung cancer. And certainly, we’ve seen the impact in clinical care, as well as improved survival outcomes.

There are several mutations that we now routinely test for in clinical practice, and the guidelines support these testing recommendations. Guidelines recommend routine testing at diagnosis of all patients with nonsquamous non–small cell lung cancer for several of these actionable mutations, including EGFR, ALK, ROS1 fusions, BRAF, KRAS, MET exon 14, RET, NTRK fusions, as well as HER2. We also do PD-L1 testing using IHC [immunohistochemistry] as a biomarker for immunotherapy.

In terms of testing methods to identify these molecular alterations, we have several ways and methods that have been used to test for these alterations. Certainly, over the years, we’ve had several ways of testing, including single-gene, multiplex, or broad testing. One of the things that has come out is that when you perform broad molecular panel-based next-generation sequencing, which is the preferred approach in my opinion, that can actually prove to be more cost effective, and you probably get more timely results. You’re doing it all in 1 setting, and this will be very important to try to reduce costs, turnaround time, as well as the need for repeat biopsies and costs associated with that. In addition, when you test with a broad-based panel, you get back 1 report, and that standardizes getting these results back for biomarkers, and hopefully, that facilitates interpretation, and then using that to guide therapy for patients with advanced non–small cell lung cancer.

We talked about how it’s something that we use for patients with advanced non–small cell lung cancer with nonsquamous histology at initial diagnosis. But what we’re also seeing is now with the approval of therapies in the adjuvant setting after surgery, we’re now doing testing earlier in the course for patients with resected non–small cell lung cancer. For patients with advanced disease, we have an initial diagnostic sample, and if there’s sufficient tissue for that patient to perform the testing on that sample, we’ll use that as the sample we’ll recommend for testing. For patients who have had surgery and have nonsquamous non–small cell lung cancer, we’re now using either the surgical sample or the biopsy prior to surgery to perform testing for EGFR, given that we now have the approval of adjuvant targeted therapy for patients with EGFR sensitizing mutations.

Transcript edited for clarity.

Related Videos
Catherine Ann Shu, MD
Christine Bestvina, MD
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, experts on lung cancer
Lyudmila A. Bazhenova, MD
Benjamin Philip Levy, MD
A panel of 6 experts on breast, lung, and gastrointestinal cancers
Mark A. Socinski, MD, an expert on lung cancer, presenting slides
Related Content
Advertisement
David Harpole, MD

AEGEAN Subgroup Analysis Fails to Demonstrate Clear Benefit With Perioperative Durvalumab Plus Chemo in EGFR+ NSCLC

December 5th 2023
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

December 4th 2023
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
Lyudmila A. Bazhenova, MD

Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC

November 30th 2023
Article
FDA

FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

November 30th 2023
Article
Related Content
Advertisement
David Harpole, MD

AEGEAN Subgroup Analysis Fails to Demonstrate Clear Benefit With Perioperative Durvalumab Plus Chemo in EGFR+ NSCLC

December 5th 2023
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

FDA Grants Fast Track Designation to BI 764532 for DLL3+ Large-Cell NEC of the Lung

December 4th 2023
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
Lyudmila A. Bazhenova, MD

Multidisciplinary Collaboration and Molecular Testing Are Integral to Treatment Decision-Making in NSCLC

November 30th 2023
Article
FDA

FDA Grants Clearance for Phase 1/2 Trial of eTIL KSQ-001EX in Solid Tumors

November 30th 2023
Article

Latest Conference Coverage

Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care

Dr Habib on Developments in Palliative Care For Patients With Cancer

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact